Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
基本信息
- 批准号:7755352
- 负责人:
- 金额:$ 37.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-01-01 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAnteriorAntiviral TherapyApoptosisBiological AssayBlindnessCD8B1 geneCaliberCellsCicatrixClinicalConfocal MicroscopyCorneaDataDeveloped CountriesEpithelialEpitheliumEyeEye diseasesFluoresceinFluoresceinsFluorescenceGrantHealedHerpesvirus 1HumanImageImmuneImmune responseImmunityImmunologyIn SituIndividualInfectionInflammatoryInflammatory ResponseKeratitisLabelLasersLeadLesionMeasuresMicrodissectionModelingModificationMolecularMolecular BiologyNatural HistoryNeuronsOryctolagus cuniculusPTPRC genePrincipal InvestigatorProteinsPublished CommentRNA analysisRecombinantsRecurrenceResolutionSimplexvirusSiteStaining methodStainsStructureStructure of trigeminal ganglionSuggestionT-LymphocyteTimeViralViral ProteinsVirusVirus Diseasesafferent nervecell typeclinically relevantcorneal scarcytokinehealingin vivoinsightprogramsprotein functionreactivated HSV-1recombinant virusresearch studyresponse
项目摘要
Our long term objective is to understand the critical immunopathologic and molecular mechanisms
underlying recurrent HSV-1 induced corneal scarring (recurrent herpetic stromal keratitis; R-HSK), a major
cause of vision loss in developed countries. Modification of an ocular HSV-1 rabbit model, which closely
mimics human R-HSK, resulted in corneal scarring in >70% of eyes (instead of <2%), allowing systematic
study of clinically relevant recurrent-HSK for the first time. Preliminary confocal microscopy (CM) studies during
latency revealed 2 distinct types of abundant subclinical corneal lesions: 1)EpiLs (epithelial lesions): Transient
(~16-24 h), punctate, small (100-200 um diameter), and consistent with replication of reactivated virus from the
trigeminal ganglia; 2)SCF (sub-clinical foci): Transient (~3-7 days) clusters of CD45+(RA+/RO+) cells (i.e., immune
cells) in the basal epithelium and anterior stroma under a healed EpiL, consistent with the CD45+ cells being
attracted to the site by transient viral Ags in the EpiL and then clearing due to lack of continued viral Ag. In
corneas without HSK, EpiLs and SCF did not overlap. Occasionally a SCF appeared to evolve into an
inflammatory stromal lesion leading to HSK, in which case an overlying EpiL was always seen. We
hypothesize that when an active SCF and an active EpiL overlap, viral Ags in the EpiL can restimulate the
hyperimmune cells in the SCF resulting in an inflammatory response and HSK. Our Specific Aims include:
1. Using in vivo CM, confirm our hypothesis that epithelial lesions (EpiLs) lead to the formation of
transient sub-clinical foci (SCF) and that SCF lead to HSK when a second EpiL occurs at the site of an existing
SCF, or when the original EpiL persists until after the SCF is fully formed. The formation and progression
(natural history) of EpiLs, SCF, and HSK from acute infection to stromal scarring will be examined daily. We will
also microinject viral Ags into the stroma to try to induce HSK.
2. Confirm our hypothesis that SCF are composed of unique subpopulations of primed immune cells
responding to viral infection. Identify and characterize immune cell infiltrates and viral Ag in SCF of CJLAT vs
wt infected corneas at pre-SCF, SCF, and pre-HSK (EpiL+SCF) times (identified using in vivo CM), by: a) Ex
vivo CM; b)In situ proliferation analyses (Ki67 mAb staining/ex vivo CM to identify and quantitate cycling
[activated] immune cells); c)Laser MicroDissection (LMD) followed by RNA analysis to detect mRNAs for rabbit
cytokines and viral proteins. GFP, YFP, RFP tagged CJLAT and wt viruses will also be employed.
3. Confirm our hypothesis that formation of EpiLs, SCF, and hence, HSK requires replication in the
cornea of reactivated HSV-1 returning from latently infected trigeminal ganglia (TG). Changes to HSK and
factors Aims 1 and 2 will be re-examined following manipulations of HSK by: a) Antiviral therapy and cutting
sensory nerves to/from TG; and b) immuno-suppressive therapy after resolution of the primary infection.
The insights obtained should help alleviate this leading cause of infectious corneal blindness. Program Director/Principal Investigator (Last, First, Middle): Wechsler, Steven Lewis
Project Narrative
This project is aimed at understanding the immunology and molecular biology of herpetic eye disease
(HSK), a leading cause of blindness in developed countries.
我们的长期目标是了解关键的免疫病理和分子机制。
潜在的复发HSV-1诱导的角膜瘢痕形成(复发性疱疹间质角膜炎;R-HSK)是一种主要的
发达国家视力丧失的原因。兔单纯疱疹病毒1型眼部模型的改进
模拟人类R-HSK,导致70%的眼睛(而不是2%)的眼睛形成角膜疤痕,允许系统性
首次对临床相关的复发性单纯疱疹病毒性角膜炎进行研究。共聚焦显微镜(CM)的初步研究
潜伏期显示了两种不同类型的丰富的亚临床角膜病变:1)EpiL(上皮病变):一过性
(~16-24小时),点状,小(100-200微米直径),与从
三叉神经节;2)SCF(亚临床病灶):一过性(~3-7天)CD45+(RA+/RO+)细胞簇(即免疫
细胞)在愈合的EPIL下,与CD45+细胞
被EPIL中的瞬时病毒AGS吸引到该部位,然后由于缺乏持续的病毒抗原而清除。在……里面
无HSK、EpiL和SCF的角膜不重叠。偶尔,SCF似乎会演变为
炎性间质病变导致HSK,在这种情况下,总是可以看到覆盖的EPIL。我们
假设当活跃的SCF和活跃的EPIL重叠时,EPIL中的病毒AGS可以重新刺激
SCF中的高免疫细胞导致炎症反应和HSK。我们的具体目标包括:
1.使用体内CM,证实了我们的假设,即上皮损伤(EpiL)导致了
暂时性亚临床病灶(SCF),当第二个EPIL发生在现有的
SCF,或者当原始EPIL持续到SCF完全形成之后。它的形成和发展
(自然病史)从急性感染到间质瘢痕形成的EpiL、SCF和HSK将每天进行检查。我们会
同时,向间质内微量注射病毒AGS,试图诱发HSK。
2.确认我们的假设,即SCF由独特的免疫细胞亚群组成
对病毒感染做出反应。CJLAT VS小鼠SCF中免疫细胞和病毒抗原的鉴定与鉴定
WT感染的角膜在SCF前、SCF前和HSK前(Epil+SCF)时间(使用活体CM识别),由:A)Ex
活体CM;b)原位增殖分析(Ki67单抗染色/体外CM以识别和定量周期
[激活的]免疫细胞);c)激光显微切割(LMD),然后进行RNA分析以检测兔的mRNAs
细胞因子和病毒蛋白。GFP、YFP、RFP标记的CJLAT和WT病毒也将被使用。
3.确认我们的假设,即EpiL、SCF的形成以及HSK的形成需要在
从潜伏感染的三叉神经节(TG)返回的重新激活的HSV-1角膜。对HSK和
目标1和2因子将在HSK操作后重新检查:a)抗病毒治疗和切割
感觉神经往返于TG;以及b)原发炎消退后的免疫抑制治疗。
所获得的见解应该有助于减轻这一感染性角膜失明的主要原因。项目主任/首席调查员(最后、第一、中间):韦克斯勒,史蒂文·刘易斯
项目叙事
本项目旨在了解疱疹病毒性眼病的免疫学和分子生物学。
(HSK),这是发达国家导致失明的主要原因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN L WECHSLER其他文献
STEVEN L WECHSLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN L WECHSLER', 18)}}的其他基金
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation
LAT-HVEM 相互作用影响 HSV-1 潜伏期/重新激活
- 批准号:
8822657 - 财政年份:2015
- 资助金额:
$ 37.87万 - 项目类别:
HSV-1 LAT miRNAs: Neurovirulence, reactivation, mechanism
HSV-1 LAT miRNA:神经毒力、再激活、机制
- 批准号:
8730998 - 财政年份:2013
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: Newly discovered LAT miRNAs and latency
角膜 HSV-1:新发现的 LAT miRNA 和潜伏期
- 批准号:
8337866 - 财政年份:2011
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
- 批准号:
7373354 - 财政年份:2008
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
- 批准号:
7539154 - 财政年份:2008
- 资助金额:
$ 37.87万 - 项目类别:
Ocular HSV-1: Preventing Recurrent Corneal Disease
眼部 HSV-1:预防复发性角膜疾病
- 批准号:
6702922 - 财政年份:2003
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG
角膜 HSV-1:LAT 阻断兔 TG 细胞凋亡
- 批准号:
6326521 - 财政年份:2001
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
- 批准号:
8466973 - 财政年份:2001
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
- 批准号:
7490424 - 财政年份:2001
- 资助金额:
$ 37.87万 - 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
- 批准号:
7892433 - 财政年份:2001
- 资助金额:
$ 37.87万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 37.87万 - 项目类别:
Research Grant














{{item.name}}会员




